Clinical trials: Oligometastatic
Metastatic Colorectal Cancer, Oligometastatic Disease
Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites
A small number of colorectal cancer patients with limited oligometastases may be candidates for local treatment of metastases (e.g., resection, ablation).
- Trial name
- SIRIUS (NCT05375708)
- Testing
- Stereotactic body radiation therapy (SBRT), Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)
- Where
- 4 sites in Netherlands
- Volunteers
- 93 people
- Sponsor
- UMC Utrecht
Esophageal Cancer, Gastric (Stomach) Cancer
Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma
Purpose of the Study: This clinical study investigates whether a shorter or longer duration of systemic therapy before local treatment (surgery or radiation) results in better disease control in patients with esophageal or…
- Conditions
- Esophageal Cancer, Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
- Trial name
- OMEC-5 (NCT07000253)
- Testing
- Chemotherapy, Targeted Systemic Therapy, Immunotherapy
- Where
- 5 sites in Netherlands, Norway and 1 more
- Volunteers
- 290 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Oligometastatic Squamous Cell Carcinoma of the Head and Neck
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
This is a randomized open-label multicentre phase III superiority study of the effect of adding SABR to the standard of care treatment pembrolizumab on progression free survival in patients with oligometastases of a squamous cell…
- Trial name
- PROLoNg (NCT05815927)
- Testing
- Pembrolizumab, stereotattic ablation radiotherapy (SABR)
- Where
- 30 sites in Belgium, Italy and 2 more
- Volunteers
- 200 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Oligometastatic Prostate Cancer
Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer
Prostate cancer represents the second most common malignancy in men worldwide. Oligometastatic prostate cancer (OMPC), defined as a transitional state between localized and widespread metastatic disease (≤10 metastatic lesions…
- Trial name
- OMPC-RPM (NCT07490210)
- Testing
- Metastasis-directed radiotherapy, Rezvilutamide + ADT, Radical prostatectomy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Oligometastatic Disease
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
Phase 2, open-label, multicenter, randomized study comparing the safety and efficacy of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) combined with immune checkpoint inhibitor (ICI) immunotherapy…
- Trial name
- NCT05846646
- Testing
- IMSA101, Immune checkpoint inhibitor, PULSAR
- Where
- 9 sites in United States
- Volunteers
- 6 people
- Sponsor
- ImmuneSensor Therapeutics Inc.
Advanced Oligometastatic Non-small Cell Lung Cancer
A Study of TQB2450 Injection Combined With Stereotactic Body Radiation Therapy (SBRT) in Subjects With Advanced Oligometastatic Non-Small Cell Lung Cancer
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and…
- Trial name
- NCT04306926
- Testing
- TQB2450, SBRT
- Where
- 4 sites in China
- Volunteers
- 59 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Prostate Cancer, Prostate Cancer Recurrent
Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer
The current trial will test the combination of darolutamide with SBRT, in oligometastatic recurrent hormone sensitive prostate cancer.
- Conditions
- Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic, Metastatic Cancer
- Trial name
- DART (NCT04641078)
- Testing
- Darolutamide, metastasis-directed treatment
- Where
- 8 sites in Belgium
- Volunteers
- 124 people
- Sponsor
- University Hospital, Ghent
Spinal Metastases, Spinal Tumor
En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor.
The purpose of this clinical trial is to explore the impact of En bloc surgery and separation surgery combined with radiation therapy on the prognosis and survival of patients with spinal oligometastatic cancer, describe the…
- Conditions
- Spinal Metastases, Spinal Tumor, Radiotherapy, Malignant Bone Tumor
- Trial name
- NCT06120426
- Testing
- total en bloc spondylectomy
- Where
- China
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Shanghai Changzheng Hospital
Melanoma Stage III, Melanoma Stage IV
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
The purpose of this study is to test the effects of anti-PI-1 inhibitor (TSR-042) or anti-PD-1/anti-TIM-3 combination (TSR-042 / TSR-022) in patients with operable melanoma.
- Trial name
- NCT04139902
- Testing
- Dostarlimab (TSR-042) (singly), Dostarlimab (TSR-042) and TSR-022 (combination)
- Where
- 5 sites in United States
- Volunteers
- 58 people
- Sponsor
- Diwakar Davar
Prostate Cancer
Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer
This study is evaluating whether adding stereotactic radiotherapy (a new, more focused type of radiotherapy) to treat all the tumours that are present will improve outcomes or not compared to drugs alone for patients who are…
- Trial name
- NCT04619069
- Testing
- SBRT, Hormone therapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Sunnybrook Health Sciences Centre
Locally Advanced Rectal Cancer (LARC)
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
The FORTRESS trial (NG-350A-03) is an open-label, single-arm, and multicentre trial of NG-350A in combination with chemoradiotherapy (CRT) in adult patients with locally advanced rectal cancer (LARC) and at least one risk factor…
- Trial name
- FORTRESS (NCT06459869)
- Testing
- NG-350A IV administration, Capecitabine oral administration, Radiotherapy
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Akamis Bio
NSCLC Stage IV, Oligometastasis
Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC
In recent years, immune checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen-4, programmed death-1, and programmed death-ligand 1 have achieved milestones in the treatment of NSCLC, from back-line to first-line, and…
- Trial name
- NCT05055583
- Testing
- Toripalimab in Combination With Platinum-based Chemotherapy, Surgical treatment stage, Adjuvant treatment stage
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tang-Du Hospital
Prostate Cancer
SBRT for Oligometastatic Castration-Refractory Prostate Cancer
Castration-resistant prostate cancer patients with rising prostatic specific antigen (PSA) are eligible for this study. 11C-Choline PET/CT will be used to identify metastatic lesions.
- Trial name
- NCT02816983
- Testing
- SBRT
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Mayo Clinic
Prostate Cancer
External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET)
This is a phase II trial to evaluate the therapeutic efficacy of a radiolabelled PSMA-targeting antibody, 177Lu-TLX591, given in combination with external beam radiation therapy (EBRT) in patients with biochemically recurrent…
- Trial name
- NCT05146973
- Testing
- 177Lu-DOTA-TLX591
- Where
- 4 sites in Australia
- Volunteers
- 5 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Esophageal Squamous Cell Carcinoma, Oligometastatic Disease
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
Patients with oligometastatic squamous cell carcinoma were enrolled and randomly assigned to receive either PD-1 inhibitor +/- chemotherapy combined with local therapy or PD-1 inhibitor +/- chemotherapy alone.
- Conditions
- Esophageal Squamous Cell Carcinoma, Oligometastatic Disease, Radiotherapy
- Trial name
- NCT06190782
- Testing
- PD-1 inhibitor+/- chemotherapy combined with local therapy, systemic therapy alone
- Where
- China
- Volunteers
- 354 people
- Sponsor
- Fudan University
Colorectal Cancer
Low and Intermediate Risk OliGometastatic ColoREctal CancEr PatieNts Treated with Stereotactic ABlative Radiotherapy
This is an experimental study without drug or device, randomized, open-label, non-profit, sponsored by the IRCCS Sacro Cuore Don Calabria Hospital in Negrar, which will take place at the Department of Advanced Oncological…
- Trial name
- GREENLaIT-SABR (NCT06310564)
- Testing
- SABR
- Where
- Italy
- Volunteers
- 204 people
- Sponsor
- IRCCS Sacro Cuore Don Calabria di Negrar
Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma
Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial
The aim of this study is to learn whether the early initiation of a specialized and focused type of radiation called stereotactic body radiation therapy (SBRT) will impact the progression of advanced adenoid cystic carcinoma…
- Trial name
- NCT04883671
- Testing
- Standard of Care, SBRT
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Oligometastatic Renal Cell Carcinoma
A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)
To learn if adding 1 year of therapy with pembrolizumab can help to continue to control RCC after radiation therapy.
- Trial name
- NCT06004336
- Testing
- Pembrolizumab, Radiation therapy
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Diagnostic and Prognostic Accuracy of FDHT-PET and Liquid Biopsies in Prostate Cancer
Depending on the cohort of the study the diagnostic and prognostic accuracy and health economics considerations of [18F]-fluoro-5α-dihydrotestosterone (FDHT)- positron emission tomography (PET) and/or circulating tumor cells in…
- Trial name
- NCT05245435
- Testing
- FDHT-PET Scan, liquid biopsies
- Where
- Austria
- Sponsor
- Medical University of Vienna
Prostate Cancer
Advanced Radiotherapy (ART) in Prostate Cancer (PROST-ART)
This is a retrospective monoinstitutional study which analyses the results of advanced radiotherapy (IGRT, IMRT, SBRT, and PET-guided) performed for radical, adjuvant, or salvage purposes in patients with low, intermediate, high…
- Trial name
- PROST-ART (NCT06546267)
- Testing
- Image Guided Radiotherapy, Intensity Modulated Radiotherapy, Stereotactic Body Radiotherapy
- Where
- Italy
- Volunteers
- 2,500 people
- Sponsor
- IRCCS San Raffaele